Bayer logo
US MEDICAL AFFAIRS
Contact Us icon

Publications

Publications

Home / Publications 

We invite you to explore our publications on hormonal and reproductive health. The publications below are authored, in part, by Bayer. This library is not intended to serve as a comprehensive repository of publications on women's healthcare. If not available at the links below, you may request the full text copy of the publications by visiting askmed.bayer.com.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated June 2024.

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 23    

Filtered results: 23

Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data

Willmann S, et al. CPT Pharmacometrics Syst Pharmacol. July 2024;00:1-13.

Willmann S, Lloyd A, Austin R, Joseph S, Solms A, Zhang Y, Schne,
READ
EMAIL

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials

Pinkerton J, et al. JAMA. Aug 2024; Online Ahead of Print.

Pinkerton J,
READ
EMAIL

Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study.

Kingsberg S, et al. Maturitas. Aug 2024; 22(189):108096.

Kingsberg A,
READ
EMAIL

Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe

Kingsberg S, et al. Maturitas. 2024 Jul; 23:188:108071.

Kingsberg S,
READ
EMAIL

Real-world clinical evaluation of natural and induced vasomotor symptoms in the USA and Europe

Kingsberg S, et al. Climacteric. May 2024; 2:1-9.

Kingsberg S,
READ
EMAIL

Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause

Pinkerton J, et al. Menopause. Apr 2024; 10-97.

Pinkerton J,
READ
EMAIL

Global view of vasomotor symptoms and sleep disturbance in menopause: a systematic review

Kingsberg SA, et al. Climacteric. 2023 Dec; 26(6):537-549.

Kingsberg,
READ
EMAIL

Risks of Uterine Perforation and Expulsion Associated With Intrauterine Devices

Fassett MJ, et al. Obstet Gynecol. Sep 2023; 142(3):641-651.

Fassett MJ,
READ
EMAIL

Utilisation, effectiveness, and safety of immediate postpartum intrauterine device insertion: a systematic literature review

Rosa Bolling K, et al. BMJ Sex Reprod Health. Apr 2023;49:e1.

Rosa Bolling K,
READ
EMAIL

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

Simon JA, et al. Menopause. Mar 2023; 30(3):239-246.

Simon JA,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2024 Bayer. Bayer and the Bayer Cross are registered trademarks for Bayer.

Site last updated 06/2024